Ge Long Hui·2025-11-13 08:56Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its development of a novel vaccine to enhance protection against tuberculosis [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenoviral vector, has officially started its Phase I clinical trials in Indonesia, with the first subject enrolled [1] - The existing BCG vaccine is the only globally available vaccine for tuberculosis prevention, but its efficacy diminishes over time and cannot be enhanced through booster shots [1] - The company has developed a first-generation innovative tuberculosis booster vaccine aimed at individuals who have received the BCG vaccine, which has shown safety and efficacy in previous clinical trials conducted in Canada [1] Group 2: Technological Advancements - The company has leveraged its technology from the development of inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses to eliminate tuberculosis bacteria and control latent infections [1]